Purdue Pharma receives US FDA nod for Butrans Transdermal System CIII for management of moderate to severe chronic pain
Tuesday, July 06, 2010 17:00 IST Stamford, Connecticut
US Food and Drug Administration (FDA) has approved Purdue Pharma LP's Butrans (buprenorphine) Transdermal System CIII for the management of moderate to severe chronic pain in patients